p53 is one of the key anti-oncogenes in multiple cancers, the activity of which is ubiquitously lost in human cancers by p53 gene mutation (60% of cancers) or by the loss of cell signaling upstream and downstream of p53 in the remaining cancers expressing p53-wild type gene.20 In the current study, we demonstrated that p53 potentially contributed to lncRNA PVT1-mediated TGF-β/Smad pathway inactivation and therefore inhibiting the occurrence and progression of glioma, revealing that p57 and lncRNA PVT1 were functionally correlated through a binding relation in glioma. The gene discussed is PVT1; the disease is central nervous system cancer.